[
  {
    "ts": null,
    "headline": "Biogen: Alzheimer's Disease Treatment Needs More Real-World Data",
    "summary": "Get insights on Biogenâs Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.",
    "url": "https://finnhub.io/api/news?id=7c904f2def5ff661061ac48f0c5d2f0669c75b4c1d5049fc24c074a4dffa10d5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765750972,
      "headline": "Biogen: Alzheimer's Disease Treatment Needs More Real-World Data",
      "id": 137788491,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/544975818/image_544975818.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Get insights on Biogenâs Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.",
      "url": "https://finnhub.io/api/news?id=7c904f2def5ff661061ac48f0c5d2f0669c75b4c1d5049fc24c074a4dffa10d5"
    }
  }
]